Literature DB >> 11546838

Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies.

F L Heppner1, C Musahl, I Arrighi, M A Klein, T Rülicke, B Oesch, R M Zinkernagel, U Kalinke, A Aguzzi.   

Abstract

Variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy are initiated by extracerebral exposure to prions. Although prion transmission from extracerebral sites to the brain represents a potential target for prophylaxis, attempts at vaccination have been limited by the poor immunogenicity of prion proteins. To circumvent this, we expressed an anti-prion protein (anti-PrP) mu chain in Prnp(o/o) mice. Transgenic mice developed sustained anti-PrP titers, which were not suppressed by introduction of Prnp+ alleles. Transgene expression prevented pathogenesis of prions introduced by intraperitoneal injection in the spleen and brain. Expression of endogenous PrP (PrP(C)) in the spleen and brain was unaffected, suggesting that immunity was responsible for protection. This indicates the feasibility of immunological inhibition of prion disease in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11546838     DOI: 10.1126/science.1063093

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  79 in total

1.  Grand ideas floating freely. Conference on the new prion biology: basic science, diagnosis and therapy.

Authors:  Bruce Chesebro
Journal:  EMBO Rep       Date:  2002-12       Impact factor: 8.807

Review 2.  Transgenesis applied to transmissible spongiform encephalopathies.

Authors:  Jean-Luc Vilotte; Hubert Laude
Journal:  Transgenic Res       Date:  2002-12       Impact factor: 2.788

3.  In vivo-application of anti-proctolin-antiserum affects antennal flight posture in crickets.

Authors:  M Gebhardt
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2004-02-13       Impact factor: 1.836

4.  Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid Polypeptide.

Authors:  Christine C Lee; Mark C Julian; Kathryn E Tiller; Fanling Meng; Sarah E DuConge; Rehana Akter; Daniel P Raleigh; Peter M Tessier
Journal:  J Biol Chem       Date:  2015-11-24       Impact factor: 5.157

Review 5.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

6.  An aggregation-specific enzyme-linked immunosorbent assay: detection of conformational differences between recombinant PrP protein dimers and PrP(Sc) aggregates.

Authors:  Tao Pan; Binggong Chang; Poki Wong; Chaoyang Li; Ruliang Li; Shin-Chung Kang; John D Robinson; Andrew R Thompsett; Po Tein; Shaoman Yin; Geoff Barnard; Ian McConnell; David R Brown; Thomas Wisniewski; Man-Sun Sy
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

7.  Testing the possibility to protect bovine PrPC transgenic Swiss mice against bovine PrPSc infection by DNA vaccination using recombinant plasmid vectors harboring and expressing the complete or partial cDNA sequences of bovine PrPC.

Authors:  Sandra Müller; Roland Kehm; Michaela Handermann; Nurith J Jakob; Udo Bahr; Björn Schröder; Gholamreza Darai
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

8.  New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products.

Authors:  David A Kocisko; Gerald S Baron; Richard Rubenstein; Jiancao Chen; Salomon Kuizon; Byron Caughey
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prions.

Authors:  Chang-Hyun Song; Osamu Honmou; Natsuo Ohsawa; Kiminori Nakamura; Hirofumi Hamada; Hidefumi Furuoka; Rie Hasebe; Motohiro Horiuchi
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Progress and problems in the biology, diagnostics, and therapeutics of prion diseases.

Authors:  Adriano Aguzzi; Mathias Heikenwalder; Gino Miele
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.